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Argininosuccinic aciduria, due to deficiency of argininosuccinic acid lyase, is generally associated with severe 
neonatal hyperammonaemia and its neurological sequelae. The cases of two siblings with this autosomal 
recessive disorder are presented. Both infants were preterm and delivered by Caesarean section for maternal 
pre-eclampsia. The first infant was not diagnosed until after the development of severe hyperammonaemia and, 
despite adequate treatment with haemodialysis and arginine infusion, remained comatose for a prolonged 
period. At 20 months she has profound developmental delays and intellectual impairment. The second infant, 
whose diagnosis was made antenatally by amniotic fluid analysis, was treated with arginine infusion beginning 
at 32 h of life and never developed hyperammonaemia. We conclude that early recognition and prompt 
institution of arginine therapy is an effective regimen for the prevention of neonatal hyperammonaemia in 
argininosuccinic aciduria. 
Argininosuccinic aciduria (ASA) (McKusick 20790) is a 
rare inherited disorder of the urea cycle characterized by 
a deficiency of the enzyme argininosuccinic acid lyase 
(AL) (EC 4.3.2.1) and the presence of large quantities of 
argininosuccinic acid and ammonia in the urine and 
body fluids. The incidence of this autosomal recessive 
disease is estimated at 1 per 70000 live births in the 
United States (Batshaw and Brusilow, 1980). The 
neonatal-onset form is associated with the development 
of hyperammonaemia and its clinical manifestations in 
the first few days of life, usually after the institution of 
protein feedings. Respiratory distress, vomiting, hy- 
potonia, convulsions and coma may ensue, and most of 
the affected infants have died in the neonatal period 
(Batshaw and Brusilow, 1980). Spongy degeneration, 
focal necrosis, and the presence of Alzheimer type II glia, 
pathognomonic of hyperammonaemic injury, have been 
demonstrated upon neuropathologic examination of the 
brains of non-survivors (Batshaw et al . ,  1982). 
Maintenance of normal plasma ammonia concentration 
is the major goal of neonatal treatment, accomplished by 
preventing excessive ammonia production or facilitating 
its removal. 
The ability of arginine therapy to prevent neonatal 
hyperammonaemia in ASA is illustrated by two siblings 
with ASA. The first infant was not diagnosed until 
significant hyperammonaemia had already developed. 
The second infant was diagnosed in utero by amniotic 
fluid analysis and received prompt arginine treatment 
which prevented the development of hyper- 
• ammonaemia. 
M E T H O D S  
Plasma ammonia concentrations were determined by 
the clinical pathology laboratory of the University of 
Michigan, using a modification of the method of Van 
1 Address for correspondence: Box 007, L3023 Women's Hospital, 
Ann Arbor, MI 48109-0010, USA. Telephone: (313) 763-4109. 
Anken and Schiphorst (1974) and an automated clinical 
analyser (DuPont ACA III). Plasma amino acids and 
urea cycle intermediates were measured by a Beckman 
ll8CL analyser. Argininosuccinic lyase activity was 
determined by the method of Fleisher et al. (1983) 
utilizing 14C-citrulline/3H-leucine incorporation into 
protein. 
Patient 1 
The first infant, a 2100g female, was delivered at 35 
weeks gestation by emergency Caesarean section for 
maternal pre-eclampsia. The Apgar scores were 8 and 10 
at 1 and 5 min, respectively and the infant appeared well 
until the fourth day of life when she became lethargic, fed 
poorly, and displayed a diminished suck and moro 
response. She rapidly deteriorated, developing apnoea, 
hypotonia, and eventually coma, requiring intubation 
and mechanical ventilation. Prior to transfer, her plasma 
ammonia concentration was 941gmol1-1. Upon ad- 
mission, she was without spontaneous activity and 
totally unresponsive to stimuli. Plasma ammonia 
concentration was 1172 gmol 1-1. She underwent 2 h of 
haemodialysis which successfully lowered plasma 
ammonia to 78 gmoll-1 but was not associated with 
neurologic improvement. A diagnosis of ASA was made 
based on elevated plasma concentrations of arginino- 
succinate (4.5 mmol 1 - 1) and citrulline (0.33 mmol 1 - 1 ), 
and marked argininosuccinic aciduria and moderate 
orotic aciduria (2.8gmolmg creatinine-1; normal 
< 0.03 p.mol mg creatinine - 1). A return of the plasma 
ammonia concentration to 496 p.moll- 1 necessitated 
the institution of intravenous 10% arginine-HC1 
therapy which was infused at 4 mmol kg- 1 day - 1 (Figure 
1). This was followed by a decrease in plasma ammonia 
concentration to 58gmol1-1 over the next 24h and 
associated with the return of superficial and deep tendon 
reflexes and spontaneous respirations. For the re- 
mainder of her hospital course, her plasma ammonia 
concentrations remained below 32 gmol l-1 and upon 
institution of oral feedings she was treated with a 
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Figure I Clinical courses of plasma ammonia concentrations 
during the first t4 days of life for two siblings with 
argininosuccinic aciduria. Broken line represents Patient 1, 
solid line represents Patient 2. ARG = arginine-HC1 infusion, 
HD = haemodialysis 
mixture of arginine (free base) and ornithine acetate 
(2 mmol kg 1 day- 1 of each). 
Patient 2 
A subsequent pregnancy was achieved by the same 
couple. Amniocentesis was performed in the 23rd week 
of the pregnancy and a diagnosis of ASA was made, 
based on the detection of argininosuccinic acid in the 
amniotic fluid (43 i.tmol 1 - 1) and deficient lyase activity 
in amniocytes; 14C-citrultine/3H-leucine incorporation 
into protein demonstrated a control value of 0.107 and a 
patient value of 0.012 using the method of Fleisher et al. 
(1983). This pregnancy was also complicated by pre- 
edampsia; spontaneous rupture of the membranes at 32 
weeks prompted maternal transfer to the University of 
Michigan where a repeat Caesarean section was 
performed. The second infant, a 1780 g male, had Apgar 
scores of 7 and 8 at 1 and 5 min, respectively. He 
developed mild hyaline membrane disease requiring 24 h 
of assisted ventilation for hypercapnia. ASA was 
confirmed by plasma and urinary amino acid analysis 
and by assay of AL activity in umbilical cord fibroblasts. 
His plasma ammonia concentration, 33gmol1-1 at 
birth, rose to a maximum of 115 btmol 1-1 at 32 h of age, 
at which time an intravenous arginine infusion was 
begun (4mmol ks-1 day-l).  After 48h of arginine 
therapy, plasma ammonia declined to 29 I.tmol 1-1 and 
thereafter never exceeded 65 gmol 1 - 1, even with dietary 
protein intake as high as 3.0gkg-1 day-1. He was 
successfully switched from intravenous arginine to oral 
arginine and ornithine acetate (2 mmol k s -  * day - i of 
each) with continued successful control of the plasma 
ammonia concentration. At no time during the neonatal 
period did he display abnormal neurological signs or 
symptoms. 
DISCUSSION 
Defects of the urea cycle preclude de novo synthesis of 
arginine and result in its becoming an essential amino 
acid in patients with these defects. In addition to 
supplying enough arginine for protein synthesis, 
arginine therapy permits patients with ASA to perform 
an "abbreviated" urea cycle commencing with ornithine 
and terminating with the excretion of a large amount of 
ASA which contains both molecules of nitrogen which 
would normally be excreted as urea if the cycle were 
intact (Brusilow and Batshaw, 1979; Batshaw and 
Brusilow, 1980; Batshaw et al., 1982). 
In AL deficiency, administered arginine is converted 
rapidly to ornithine and subsequently to ASA by the 
intact enzymes of the urea cycle (Batshaw et al., 1981). 
The efficacy of arginine therapy is conditional upon 
early diagnosis and treatment. In the first patient, the 
development of profound and life-threatening hyper- 
ammonaemia required immediate intervention. We 
(Donnet  al., 1979) and others (Wiegand et al., 1980) 
have demonstrated the safety and efficacy of haemo- 
dialysis for the treatment of hyperammonaemia in the 
newborn using the readily accessible umbilical artery 
and vein. As shown in the figure, the plasma ammonia 
concentration in the first infant fell to normal values 
after only 2 h of haemodialysis; however, the effect was 
transient and arginine therapy was required to maintain 
normal plasma ammonia concentration. In utero 
diagnosis (Goodman et al., 1973, Collins et al., 1980; 
Fleisher et al., 1983) in the second infant permitted 
institution of treatment prior to the development of 
significant hyperammonaemia. This obviated the need 
for either haemodialysis or peritoneal dialysis and their 
inherent risks and complications. 
Table 1 displays the effect of arginine treatment on the 
plasma concentrations of urea cycle intermediates in the 
two patients. Post-treatment determinations were made 
after the patients had received 24 h of a continuous 
infusion of arginine at a dose of 4 mmol kg - 1 day- 1. It is 
interesting to note that in both cases the plasma ASA 
concentration equilibrated at about the same level 
(1910-1850 btmol 1-1) with treatment at the same dose, 
but these values were approached from opposite 
directions. Homeostasis under these circumstances 
depends upon supplying adequate arginine for effective 
Table I The effect of arginine treatment on the concentration 
of urea cycle intermediates in plasma 0tmol ! - t )  
Citrulline ASA Arg Orn 
Patient 1 
pretreatment 327 4506 46 ND 
post-treatment 847 19t0 360 211 
Patient 2 
pretreatment 51 544 44 43 
post-treatment 310 1850 184 47 
Normal range <30 ND 54 + 17 91 + 25 
ND, not detectable 
ASA, argininosuccinic acid 
Arg, arginine 
Orn, ornithine 
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ammonia removal and also upon adequate renal 
function to dispose of the ASA thus generated. 
Intravenous arginine therapy in both infants was 
associated only with a mild persistent metabolic acidosis 
which responded to supplemental sodium bicarbonate 
therapy. This may have resulted from the hydrochloride 
salt of arginine; when both infants were switched to the 
oral preparation of arginine as the free 'base' and 
ornithine acetate, the metabolic acidosis resolved 
without the need for alkali therapy. 
Treatment of inborn errors of the urea cycle has 
advanced greatly in the past decade with the advent of 
alternative methods of waste nitrogen disposal. Early 
diagnosis and treatment of arginosuccinate lyase 
deficiency with arginine appears to be a highly effective 
management of potentially lethal hyperammonaemia in 
the newborn period. Msall et al. (1984) recently 
demonstrated the association between prolonged neo- 
natal hyperammonaemic coma with brain damage and 
impaired intellectual function in children with urea cycle 
enzymopathies. Although the long-term prognosis for 
individuals with arginosuccinate lyase deficiency suc- 
cessfully managed in the neonatal period is unknown, 
the avoidance of neonatal hyperammonaemia and its 
catastrophic complications appears achievable. 
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